Alnylam Pharmaceuticals Announces Positive HELIOS-B Phase 3 Results for AMVUTTRA® (Vutrisiran), Showing Reduced GI Events in ATTR-CM Patients
Alnylam Pharmaceuticals Inc. announced positive results from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), showing a 37-49% reduction in gastrointestinal adverse events compared to placebo in ATTR-CM patients. The findings, presented at the HFSA Annual Scientific Meeting 2025, support the safety and efficacy of vutrisiran and its recent approvals in multiple regions, including the US and EU.
Alnylam Pharmaceuticals Inc. has announced new analyses from the HELIOS-B Phase 3 study evaluating AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of wild-type or hereditary transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) and hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN) in adults. The results, which were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025, indicate that vutrisiran treatment was associated with 37-49% lower rates of gastrointestinal adverse events compared to placebo across multiple treatment groups. The findings also reinforce the safety and efficacy profile of vutrisiran as a monotherapy and demonstrate a consistent benefit across a range of patient baseline characteristics. These data support the recent approvals of AMVUTTRA for ATTR-CM in several regions, including the United States, European Union, Japan, Brazil, UAE, and the United Kingdom. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928990563) on September 28, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
